A research perspective on sphingolipid metabolism and myalgic encephalomyelitis/chronic fatigue syndrome.
Xiao, Junhua · Neural regeneration research · 2026 · DOI
Quick Summary
This study examines how the body breaks down and uses a type of fat called sphingolipids, which are important for nerve cell function and communication. The researchers reviewed existing knowledge about sphingolipid metabolism to understand whether problems in this process might contribute to ME/CFS symptoms like fatigue and pain. This perspective piece suggests that disruptions in how the body handles these fats could potentially play a role in the disease, though more research is needed to confirm this.
Why It Matters
Understanding the molecular mechanisms underlying ME/CFS is crucial for developing targeted treatments. If sphingolipid metabolism disruption is confirmed as a contributing factor, it could open new diagnostic and therapeutic avenues for patients who currently lack effective biomarkers and disease-modifying therapies.
Observed Findings
Sphingolipids play critical roles in nervous system function and immune regulation
Disruptions in sphingolipid metabolism can contribute to neuroinflammatory processes
Energy metabolism abnormalities in ME/CFS may intersect with lipid metabolic pathways
Sphinglipid signaling molecules can modulate immune cell activation and inflammatory responses
Inferred Conclusions
Sphingolipid metabolism dysfunction may represent a mechanistic link between cellular energy depletion and neuroinflammation in ME/CFS
Lipid metabolism pathways warrant investigation as potential biomarkers and therapeutic targets in ME/CFS
Integrative investigation of lipid metabolism disorders could advance understanding of ME/CFS heterogeneity
Remaining Questions
Are sphingolipid metabolite levels or enzyme activities abnormal in ME/CFS patients compared to healthy controls?
Which specific sphingolipid pathway disruptions (if any) correlate with symptom severity or disease subtypes?
Could sphingolipid metabolism interventions improve energy production or reduce neuroinflammation in ME/CFS?
What This Study Does Not Prove
This perspective article does not provide direct experimental evidence that sphingolipid metabolism is abnormal in ME/CFS patients, nor does it establish causation. It presents a theoretical framework requiring validation through patient-level studies with biological measurements and mechanistic experiments.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How do sphingolipid metabolism abnormalities interact with other proposed ME/CFS mechanisms (mitochondrial dysfunction, immune dysregulation, post-exertional malaise)?